Clinical trials: AD
Alzheimer Disease, Benson's Disease
Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD)
Recently revised Alzheimer Disease (AD) diagnostic1described nonamnestic presentations: 1/ language presentation (logopenic progressive aphasia) 2/ visuospatial presentation (posterior cortical atrophy or PCA) and 3/ executive…
- Trial name
- TEPTAU (NCT03022968)
- Testing
- [18F]T807 PET
- Where
- France
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Alzheimer Disease
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl
The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.
- Trial name
- NCT06439992
- Testing
- 18F-Fluselenamyl
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Atopic Dermatitis (AD)
CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis
This is an open-label, randomised, comparative, prospective, interventional study of a cosmetic product.
- Trial name
- DA_CeraVe (NCT07204561)
- Testing
- CeraVe Moisturizing Cream, Galenico
- Where
- Italy
- Volunteers
- 98 people
- Sponsor
- Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse
Alzheimer's Disease
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate…
- Trial name
- NOURISH-AD (NCT01741194)
- Testing
- AC-1204
- Where
- 82 sites in United States
- Volunteers
- 418 people
- Sponsor
- Cerecin
Alzheimer's Disease
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored.
- Trial name
- NCT02754830
- Testing
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Atopic Dermatitis
Pediatric Atopic Dermatitis (AD) Internet Survey
The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve atopic dermatitis treatment outcomes.
- Trial name
- NCT01385527
- Testing
- Weekly Internet survey, Topical Triamcinolone
- Sponsor
- Wake Forest University
Breast Cancer Nos Metastatic Recurrent
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
Phase II, randomized, safety and efficacy study in recurrent/metastatic breast cancer with accessible lesions. Primary End point is rate of Progression Free Survival (PFS) at the 16 week treatment time point.
- Trial name
- NCT01703754
- Testing
- Ad-RTS-hIL-12 and Veledimex, Palifosfamide
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Effectiveness of Genistein in Mild Cognitive Impairment
Randomized, placebo-controlled, double-blind, multicenter clinical trial with two parallel study arms (experimental and placebo) to assess the efficacy of genistein extract consumption over 18 months on cognitive decline in…
- Trial name
- EXTRAGENIAL (NCT07385937)
- Testing
- Genistein
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Universidad Católica San Antonio de Murcia
Treatment Resistant Bipolar Depression
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar Depression
This study is testing a new oral ketamine treatment called KET-AD in adults with treatment-resistant bipolar depression (TRBD). The study will look at how safe and tolerable the treatment is, and whether it may help improve…
- Trial name
- NCT07644767
- Testing
- KET-AD
- Volunteers
- 160 people
- Sponsor
- Neurocentrx Pharma Pty Ltd
Alzheimer Disease (AD)
[18F]F-AraG PET Imaging in Alzheimer's Disease
This study evaluates the use of [18F]F-AraG PET/CT imaging to quantify activated T cell involvement in patients with Alzheimer's disease (AD).
- Trial name
- NCT07611357
- Testing
- Drug: [18F]F-AraG (PET tracer)
- Volunteers
- 10 people
- Sponsor
- CellSight Technologies, Inc.
Alzheimer Disease
Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease (TRANSFORM-AD)
The goal of this study is to explore the efficacy and safety of transcranial alternating current stimulation (tACS) in patients with mild Alzheimer's disease (AD).
- Trial name
- NCT03920826
- Testing
- transcranial alternating current stimulation
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Xuanwu Hospital, Beijing
Mild Cognitive Impairment, Alzheimer Dementia (AD)
Closed-Loop Brain Stimulation as a Potential Intervention for Cognitive Decline
The goal of this clinical study is to investigate the effectiveness of non-invasive stimulation to enhance cognitive control abilities in older adults with and without cognitive impairment.
- Trial name
- NCT05907343
- Testing
- Closed-loop TBS, Open-loop TBS
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Atopic Dermatitis
Collection of Clinical and Instrumental Data in Adult Subjects Suffering From Atopic Dermatitis
Atopic dermatitis represents a real challenge in public health as it affects a large percentage of children and adults. Affected individuals must cope with a significant psychosocial burden, in addition to dealing with the…
- Trial name
- NCT04553224
- Testing
- Clinical evaluations, Non-invasive instrumental measurements, Subject's evaluations
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Alzheimer's Disease
Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00411580
- Testing
- CAD106
- Where
- 3 sites in Sweden
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer s Disease, Alzheimer Dementia (AD)
Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs
This research proposal outlines a multi-center, randomized, trial. Patients diagnosed with early-to-moderate Alzheimer's Disease will be recruited. Participants will be randomly assigned to receive either Lecanemab.
- Conditions
- Alzheimer s Disease, Alzheimer Dementia (AD), MCI-AD, Early Stage Alzheimer's Disease
- Trial name
- NCT07604896
- Testing
- Lecanemab 10 mg/kg, Conventional anti-dementia treatment group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Atopic Dermatitis
CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis
This is a phase III study to investigate the safety and efficacy of PAC-14028 cream in Atopic Dermatitis patients.
- Trial name
- NCT02965118
- Testing
- PAC-14028 cream 1.0%, PAC-14028 cream Vehicle
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Amorepacific Corporation
Alzheimer's Disease (AD)
Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study
Alzheimer's disease (AD) is a neurodegenerative disorder affecting almost 6% of the world's population over the age of 65. This disease, in its most typical sporadic form, is characterized by an episodic memory impairment linked…
- Trial name
- PINK-AD (NCT04570761)
- Testing
- Dreem headband
- Where
- France
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Healthy
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses
The purpose of this study is to assess safety, tolerability and pharmacokinetics of AZD1446 in young and elderly healthy Japanese volunteers.
- Trial name
- NCT01199315
- Testing
- AZD1446
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability
Patients with Alzheimer's disease (AD) can have seizures in addition to losing their memory and other mental functions (referred to as cognitive functions).
- Trial name
- LEV-AD (NCT02002819)
- Testing
- levetiracetam
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Minnesota